West Pharma (WST) Tops Q3 EPS by 35c, provides guidance
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $362.31 -1.17%
EPS Growth %: +11.7%
Financial Fact:
Interest expense: 2.2M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +11.7%
Financial Fact:
Interest expense: 2.2M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q3 EPS of $1.85, $0.35 better than the analyst estimate of $1.50. Revenue for the quarter came in at $746.9 million versus the consensus estimate of $709.3 million.
GUIDANCE:
West Pharma sees FY2024 EPS of $6.55-$6.75, versus the consensus of $6.41. West Pharma sees FY2024 revenue of $2.875-2.905 billion, versus the consensus of $2.874 billion.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Leidos wins $85m Air Force contract for aerospace design
- Westinghouse said to seek over $50 billion valuation in planned IPO
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
